AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21682858 — intervention group
Group type: EXPERIMENTAL
Intervention: On-site Research Ethics course (3.5 days)
Number of subjects: 58
Study 21682858 — intervention group
Group type: COMPARATOR
Intervention: On-line Research Ethics course (3.5 weeks)
Number of subjects: 58
Study 18550399 — intervention group
Group type: EXPERIMENTAL
Intervention: M6G 30 mg/70 kg
Number of subjects: 170
Study 18550399 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study 18550399 — intervention group
Group type: EXPERIMENTAL
Intervention: M6G (10 mg/70 kg and 20 mg/70 kg)
Number of subjects: 170
Study 18550399 — intervention group
Group type: EXPERIMENTAL
Intervention: M6G
Number of subjects: 170
Study 17803344 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin therapy (30,000 U/kg/day for 3 days)
Number of subjects: 27
Study 17803344 — intervention group
Group type: COMPARATOR
Intervention: IVIG therapy (1 g/kg/dose)
Number of subjects: 27
Study 14729733 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid 600 mg orally every 12 h for a total of six doses
Number of subjects: 11
Study 11238753 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 g dietary fiber (wheat bran) supplementation for 1 month
Number of subjects: 26
Study 11238753 — intervention group
Group type: COMPARATOR
Intervention: Soy protein supplementation (longer-term for 1 month or short-term for 4 days)
Number of subjects: 26
Study 9720743 — intervention group
Group type: EXPERIMENTAL
Intervention: glycl‐L‐glutamine
Number of subjects: 34
Study 9720743 — intervention group
Group type: COMPARATOR
Intervention: isonitrogenous mixture of non‐essential amino acids
Number of subjects: 34
Study 8054116 — intervention group
Group type: EXPERIMENTAL
Intervention: Groups led by content experts
Number of subjects: 211
Study 8054116 — intervention group
Group type: COMPARATOR
Intervention: Groups led by non-experts
Number of subjects: 211
Study 8054116 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (expert and non-expert)
Number of subjects: 211
Study 2567903 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin/clavulanate ('Augmentin') alone (36 patients)
Number of subjects: 105
Study 2567903 — intervention group
Group type: COMPARATOR
Intervention: Myringotomy plus placebo (35 patients)
Number of subjects: 105
Study 2567903 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmentin plus myringotomy (34 patients)
Number of subjects: 105
Study 2567903 — intervention group
Group type: EXPERIMENTAL
Intervention: Myringotomy plus augmentin (34 patients)
Number of subjects: 105
Study 30897584 — intervention group
Group type: EXPERIMENTAL
Intervention: ONO‐8539 (450 mg)
Number of subjects: 27
Study 30897584 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 30720005 — intervention group
Group type: EXPERIMENTAL
Intervention: Alzheimer's Disease (AD)
Number of subjects: 120
Study 30720005 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary Open-Angle Glaucoma (POAG)
Number of subjects: 120
Study 30720005 — intervention group
Group type: EXPERIMENTAL
Intervention: Preperimetric Glaucoma (PPG)
Number of subjects: 120
Study 30720005 — intervention group
Group type: COMPARATOR
Intervention: Healthy Controls
Number of subjects: 120
Study 28086976 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored program (workshop for GPs, educational materials, reminders for patients, implementation action plans)
Number of subjects: 273
Study 28086976 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored program
Number of subjects: 273
Study 28086976 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 273
Study 27549500 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking at preferred speed
Number of subjects: 50
Study 27549500 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking slower than preferred speed
Number of subjects: 50
Study 27549500 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking faster than preferred speed
Number of subjects: 50
Study 27549500 — intervention group
Group type: EXPERIMENTAL
Intervention: First test of PCI estimation
Number of subjects: 50
Study 27549500 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking at varying distances (50m, 100m, 150m)
Number of subjects: 50
Study 23940231 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus the 4-week yoga intervention (YOCAS program: pranayama, 16 Gentle Hatha and Restorative yoga asanas, and meditation; 2 sessions per week of 75 minutes each)
Number of subjects: 410
Study 23940231 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 410
Study 21458058 — intervention group
Group type: EXPERIMENTAL
Intervention: Midlevel providers (200 mg mifepristone followed by 800 μg misoprostol vaginally 2 days later)
Number of subjects: 1077
Study 21458058 — intervention group
Group type: COMPARATOR
Intervention: Doctors (200 mg mifepristone followed by 800 μg misoprostol vaginally 2 days later)
Number of subjects: 1077
Study 21458058 — intervention group
Group type: COMPARATOR
Intervention: Doctors
Number of subjects: 1077
Study 21458058 — intervention group
Group type: EXPERIMENTAL
Intervention: Midlevel providers
Number of subjects: 1077
Study 19922879 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir
Number of subjects: 443
Study 19922879 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 443
Study 19922879 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir (twice-daily)
Number of subjects: 443
Study 19922879 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir (once-daily)
Number of subjects: 443
Study 17019296 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate NaHCO3 intake (0.3 g x kg(‐1) x d(‐1))
Number of subjects: 24
Study 17019296 — intervention group
Group type: EXPERIMENTAL
Intervention: High NaHCO3 intake (0.5 g x kg(‐1) x d(‐1))
Number of subjects: 24
Study 17019296 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 24
Study 12762604 — intervention group
Group type: EXPERIMENTAL
Intervention: Concise sealant (3M)
Number of subjects: 22
Study 12762604 — intervention group
Group type: COMPARATOR
Intervention: Dyract seal (Dentsply DeTrey)
Number of subjects: 22
Study 11093490 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal circulation (group A)
Number of subjects: 108
Study 11093490 — intervention group
Group type: COMPARATOR
Intervention: Off-pump beating heart revascularization (group B)
Number of subjects: 108
Study 8959154 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous bacille Calmette‐Guérin (BCG) vaccination
Number of subjects: 30
Study 1572703 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass fibre splinting bandages
Number of subjects: 0
Study 1572703 — intervention group
Group type: COMPARATOR
Intervention: Non-glass bandages
Number of subjects: 0
Study 1572703 — intervention group
Group type: COMPARATOR
Intervention: Plaster-of-Paris bandages
Number of subjects: 0
Study 3911963 — intervention group
Group type: EXPERIMENTAL
Intervention: suprofen syrup
Number of subjects: 115
Study 3911963 — intervention group
Group type: COMPARATOR
Intervention: paracetamol syrup
Number of subjects: 115
Study 31332929 — intervention group
Group type: EXPERIMENTAL
Intervention: Flash glucose monitoring system
Number of subjects: 19
Study 30233184 — intervention group
Group type: EXPERIMENTAL
Intervention: Victimization (physical or sexual assault)
Number of subjects: 703
Study 30233184 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttraumatic stress disorder (PTSD) diagnosis
Number of subjects: 703
Study 30233184 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptoms severity
Number of subjects: 703
Study 30233184 — intervention group
Group type: EXPERIMENTAL
Intervention: Suicide risk
Number of subjects: 703
Study 30233184 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical health status
Number of subjects: 703
Study 30233184 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life (QoL)
Number of subjects: 703
Study 30233184 — intervention group
Group type: EXPERIMENTAL
Intervention: Path analysis of PTSD and violent victimization
Number of subjects: 703
Study 26644241 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone (50 mg, oral)
Number of subjects: 10
Study 26644241 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 26535762 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-item self-rated mental health (SRMH) measure
Number of subjects: 239
Study 26535762 — intervention group
Group type: COMPARATOR
Intervention: Davidson Trauma Scale for PTSD
Number of subjects: 239
Study 26535762 — intervention group
Group type: COMPARATOR
Intervention: Edinburgh Postnatal Depression Scale for depression
Number of subjects: 239
Study 24041860 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (2 mg/kg-2 ml)
Number of subjects: 75
Study 24041860 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg-2 ml)
Number of subjects: 75
Study 24041860 — intervention group
Group type: COMPARATOR
Intervention: Control (2 ml serum physiologic)
Number of subjects: 75
Study 19804945 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers with low confidence to control abstinence-induced symptoms facing internal stimuli (e.g., feeling depressed)
Number of subjects: 576
Study 19804945 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers with low confidence to control abstinence-induced symptoms facing external stimuli (e.g., during a celebration)
Number of subjects: 576
Study 17976891 — intervention group
Group type: EXPERIMENTAL
Intervention: 15:2 CPR protocol
Number of subjects: 26
Study 17976891 — intervention group
Group type: EXPERIMENTAL
Intervention: 30:2 CPR protocol
Number of subjects: 26
Study 17976891 — intervention group
Group type: COMPARATOR
Intervention: Comparison of 15:2 and 30:2 CPR protocols
Number of subjects: 26
Study 16153777 — intervention group
Group type: EXPERIMENTAL
Intervention: CB pain management training (PMT)
Number of subjects: 158
Study 16153777 — intervention group
Group type: COMPARATOR
Intervention: Education/attention control condition (self-care management, SCM)
Number of subjects: 158
Study 12576897 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin injection (20 to 30 U, approximately 0.3 U/kg)
Number of subjects: 111
Study 12576897 — intervention group
Group type: COMPARATOR
Intervention: Lateral internal sphincterotomy
Number of subjects: 111
Study 12576897 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin injection
Number of subjects: 111
Study 10494574 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone 20 mg administered twice daily for 10 days
Number of subjects: 0
Study 10494574 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7566521 — intervention group
Group type: EXPERIMENTAL
Intervention: Sabeluzole
Number of subjects: 33
Study 7566521 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 1952269 — intervention group
Group type: EXPERIMENTAL
Intervention: 160 mg propranolol
Number of subjects: 62
Study 1952269 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg metoprolol
Number of subjects: 62
Study 1952269 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 62
Study 6988945 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (200 mg before operation and 100 mg daily for 5 days)
Number of subjects: 118
Study 6988945 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (adequate prophylaxis in 159 patients)
Number of subjects: 118
Study 6988945 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (preoperatively for intra-abdominal infection in 11 patients)
Number of subjects: 118
Study 6988945 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis (incomplete or no prophylaxis in 12 patients)
Number of subjects: 118
Study 6988945 — intervention group
Group type: COMPARATOR
Intervention: Non-contaminated operations
Number of subjects: 118
Study 6988945 — intervention group
Group type: COMPARATOR
Intervention: Contaminated operations
Number of subjects: 118
Study 30814561 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual observation of a mannequin body from a first-person perspective
Number of subjects: 80
Study 30814561 — intervention group
Group type: COMPARATOR
Intervention: Conditions including touch to participants' own, unseen body
Number of subjects: 80
Study 30814561 — intervention group
Group type: COMPARATOR
Intervention: Slow, affective touch on participants' own, unseen body
Number of subjects: 80
Study 30814561 — intervention group
Group type: COMPARATOR
Intervention: Fast, non-affective touch on participants' own, unseen body
Number of subjects: 80
Study 28252371 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice‐yearly routine restaurant inspection
Number of subjects: 151
Study 28252371 — intervention group
Group type: COMPARATOR
Intervention: Standard once‐yearly routine inspection
Number of subjects: 151
Study 25747719 — intervention group
Group type: EXPERIMENTAL
Intervention: Children's Hospital at Montefiore Joining Academics and Movement (CHAM JAM) - an audio CD with 10-minute aerobic activities led by teachers three times a day.
Number of subjects: 988
Study 25747719 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 988
Study 22958078 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 2.5 mg
Number of subjects: 612
Study 22958078 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 5.0 mg
Number of subjects: 612
Study 22958078 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 612
Study 22013798 — intervention group
Group type: EXPERIMENTAL
Intervention: Wuzhi Capsule (WC)
Number of subjects: 73
Study 22013798 — intervention group
Group type: COMPARATOR
Intervention: Control (Tac + MMF + Pred)
Number of subjects: 73
Study 18286351 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose steroid therapy (prednisolone 0.4 mg/kgBW/day, tapered to 5-10 mg/day over 24 months)
Number of subjects: 48
Study 18286351 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose steroid therapy (prednisolone)
Number of subjects: 48
Study 18286351 — intervention group
Group type: COMPARATOR
Intervention: Control group (dipyridamole or zilazep hydrochloride 150 or 300 mg/day)
Number of subjects: 48
Study 18286351 — intervention group
Group type: COMPARATOR
Intervention: Control group (dipyridamole or zilazep hydrochloride)
Number of subjects: 48
Study 17132537 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludrocortisone (800 microg/day)
Number of subjects: 0
Study 17132537 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (3 mg/day)
Number of subjects: 0
Study 17132537 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 14529881 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced CsA dose (5 mg/kg/d) and daclizumab (group A, n = 16)
Number of subjects: 32
Study 14529881 — intervention group
Group type: COMPARATOR
Intervention: Normal CsA dose (10 mg/kg/day) without daclizumab (group B, n = 16)
Number of subjects: 32
Study 14529881 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced CsA dose (5 mg/kg/d) and daclizumab (group A)
Number of subjects: 32
Study 14529881 — intervention group
Group type: COMPARATOR
Intervention: Normal CsA dose (10 mg/kg/day) without daclizumab (group B)
Number of subjects: 32
Study 14529881 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 32
Study 11113421 — intervention group
Group type: EXPERIMENTAL
Intervention: sublingual estradiol 17beta
Number of subjects: 16
Study 11113421 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study 1532534 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril 1.25-10 mg/day
Number of subjects: 4500
Study 1532534 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril
Number of subjects: 4500
Study 1532534 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4500
Study 1532534 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril 5.0 mg/day + Hydrochlorothiazide 12.5 mg/day
Number of subjects: 4500
Study 1532534 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril 2.5-5 mg/day
Number of subjects: 4500
Study 1532534 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril + Hydrochlorothiazide
Number of subjects: 4500
Study 3921597 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.02 mg/kg NAL infusion
Number of subjects: 4
Study 3921597 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg NAL infusion
Number of subjects: 4
Study 3921597 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg NAL infusion
Number of subjects: 4
Study 3921597 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 4
Study 3921597 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of NAL
Number of subjects: 4
Study 3921597 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher doses of NAL
Number of subjects: 4
Study 31664143 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontitis
Number of subjects: 1064
Study 31664143 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 1064
Study 31664143 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking status
Number of subjects: 1064
Study 31664143 — intervention group
Group type: EXPERIMENTAL
Intervention: Education level
Number of subjects: 1064
Study 31664143 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes mellitus
Number of subjects: 1064
Study 30293878 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 75 mg every 2 weeks (Q2W) or 150 mg Q2W
Number of subjects: 655
Study 30293878 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 655
Study 30293878 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 655
Study 27687342 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisource feedback with monthly coaching meetings
Number of subjects: 28
Study 27687342 — intervention group
Group type: COMPARATOR
Intervention: Control group (no monthly coaching meetings)
Number of subjects: 28
Study 24652690 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadoxetic acid-enhanced MRI
Number of subjects: 360
Study 24652690 — intervention group
Group type: COMPARATOR
Intervention: ECCM-MRI
Number of subjects: 360
Study 24652690 — intervention group
Group type: COMPARATOR
Intervention: CE-CT
Number of subjects: 360
Study 22227740 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-exposure to the to-be-conditioned context (n = 20)
Number of subjects: 40
Study 22227740 — intervention group
Group type: COMPARATOR
Intervention: Unrelated virtual environment (control group, n = 20)
Number of subjects: 40
Study 21189213 — intervention group
Group type: EXPERIMENTAL
Intervention: Core weave stitch with three, five, or seven throws
Number of subjects: 21
Study 21189213 — intervention group
Group type: COMPARATOR
Intervention: Krackow stitch with three, five, or seven throws
Number of subjects: 21
Study 18796350 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate (5 g) before each chemotherapy course and magnesium subcarbonate (500 mg) three times per day orally during treatment intervals
Number of subjects: 40
Study 18796350 — intervention group
Group type: COMPARATOR
Intervention: Placebo instead of magnesium salts
Number of subjects: 40
Study 15812765 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic brimonidine
Number of subjects: 137
Study 15812765 — intervention group
Group type: COMPARATOR
Intervention: No prophylactic brimonidine
Number of subjects: 137
Study 15812765 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic brimonidine in hypertensive patients
Number of subjects: 137
Study 15812765 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic brimonidine in diabetic patients
Number of subjects: 137
Study 15812765 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic brimonidine in patients on anticoagulant or antiplatelet treatment
Number of subjects: 137
Study 12192690 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest compressions
Number of subjects: 0
Study 12192690 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilatory volume
Number of subjects: 0
Study 12192690 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic waveform defibrillators and automated external defibrillators
Number of subjects: 0
Study 12192690 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-catecholaminergic vasopressors
Number of subjects: 0
Study 12192690 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 0
Study 12192690 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary reperfusion strategies
Number of subjects: 0
Study 10524634 — intervention group
Group type: EXPERIMENTAL
Intervention: UDCA 900 mg/day
Number of subjects: 24
Study 10524634 — intervention group
Group type: EXPERIMENTAL
Intervention: UDCA 1200 mg/day
Number of subjects: 24
Study 10524634 — intervention group
Group type: COMPARATOR
Intervention: UDCA 300 mg/day
Number of subjects: 24
Study 10524634 — intervention group
Group type: COMPARATOR
Intervention: UDCA 600 mg/day
Number of subjects: 24
Study 10524634 — intervention group
Group type: COMPARATOR
Intervention: UDCA 0 mg/day (placebo)
Number of subjects: 24
Study 8645641 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction fetal scalp electrode
Number of subjects: 100
Study 8645641 — intervention group
Group type: COMPARATOR
Intervention: Spiral electrode
Number of subjects: 100
Study 1617251 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-deoxyadenosine (2-DXA)
Number of subjects: 0
Study 1617251 — intervention group
Group type: COMPARATOR
Intervention: Control (unexposed samples)
Number of subjects: 0
Study 1617251 — intervention group
Group type: COMPARATOR
Intervention: Control (unwashed sperm without 2-DXA)
Number of subjects: 0
Study 6387689 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg nocte
Number of subjects: 51
Study 6387689 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 31881910 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein total diet replacement (35% carbohydrate, 40% protein, 25% fat)
Number of subjects: 0
Study 31881910 — intervention group
Group type: COMPARATOR
Intervention: Control diet (55% carbohydrate, 15% protein, 30% fat)
Number of subjects: 0
Study 30390684 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK561679
Number of subjects: 88
Study 30390684 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 27848209 — intervention group
Group type: EXPERIMENTAL
Intervention: FitEx
Number of subjects: 12
Study 27848209 — intervention group
Group type: COMPARATOR
Intervention: ALED
Number of subjects: 12